Torin 1

Catalog No.S2827

Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.

Price Stock Quantity  
USD 170 In stock
USD 370 In stock
USD 670 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Torin 1 Chemical Structure

Torin 1 Chemical Structure
Molecular Weight: 607.62

Validation & Quality Control

4 customer reviews :

Quality Control & MSDS

Related Compound Libraries

mTOR Inhibitors with Unique Features

Product Information

  • Compare mTOR Inhibitors
    Compare mTOR Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.
Targets mTORC1 [1]
(Cell-free assay)
mTOR [2]
(Cell-free assay)
DNA-PK [2]
(Cell-free assay)
mTORC2 [1]
(Cell-free assay)

 View  More

IC50 2 nM 4.32 nM 6.34 nM 10 nM
In vitro Torin1 inhibits phosphorylation of mTORC1 and mTORC2 substrates in cells at concentrations of 2 and 10 nM, respectively. Moreover, Torin1 exhibits 1000-fold selectivity for mTOR over PI3K (EC50 = 1800 nM) and exhibits 100-fold binding selectivity relative to 450 other protein kinases. [1] [2] Torin1 causes cell cycle arrest through a rapamycin-resistant mechanism that is also independent of mTORC2. Torin1 disrupts mTORC1-dependent phenotypes more completely than rapamycin. Rapamycin-resistant functions of mTORC1 are required for cap-dependent translation. [1] In a recent study, it is reported Torin1 increases neurotensin secretion and gene expression through activation of the MEK/ERK/c-Jun pathway in the human endocrine cell line BON. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
ETK-1M4PTTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX3ySnF4UUN3ME2wMlAxODNyNjFOwG0>MnK4V2FPT0WU
OCUB-MMXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2fSWGlEPTB;MD6wNFE6PCEQvF2=NXK0U25pW0GQR1XS
DOHH-2Mn;uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEW5foFKSzVyPUCuNFAzOjVizszNNXW4SXRWW0GQR1XS
NOS-1MmLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mo\mTWM2OD1yLkCwNlQzKM7:TR?=NXXjVG1qW0GQR1XS
L-363NUPFS4JqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NG[zW|ZKSzVyPUCuNFAzQDRizszNMn;6V2FPT0WU
RL95-2MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnL2TWM2OD1yLkCwN|Ih|ryPMY\TRW5ITVJ?
BL-70MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFPxR4dKSzVyPUCuNFA{OzdizszNM3HrNXNCVkeHUh?=
TGBC1TKBNYi3W5ltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{HmbWlEPTB;MD6wNFM4QSEQvF2=M3;0OHNCVkeHUh?=
697MmXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV3rZWFnUUN3ME2wMlAxPjN2IN88US=>Mmj1V2FPT0WU
RPMI-8226MmPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn7PTWM2OD1yLkCwOlUyKM7:TR?=M3PtXHNCVkeHUh?=
BL-41MnrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3LTbWlEPTB;MD6wNFY6PiEQvF2=M17OSXNCVkeHUh?=
MRK-nu-1M1;qfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVTzXGhnUUN3ME2wMlAxPzB5IN88US=>MX3TRW5ITVJ?
EW-1NYKxOZJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUXv[XJRUUN3ME2wMlAxPzR7IN88US=>Mkf5V2FPT0WU
EVSA-TMnX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWL3XotRUUN3ME2wMlAxQDl{IN88US=>M{D4fXNCVkeHUh?=
HUTU-80NVzuNpVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mk\HTWM2OD1yLkCwPVI6KM7:TR?=MY\TRW5ITVJ?
VA-ES-BJNWD6bFh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1\HNmlEPTB;MD6wNFk5PCEQvF2=NH;Se5ZUSU6JRWK=
GCIYMVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlfTTWM2OD1yLkCxNFA4KM7:TR?=MXHTRW5ITVJ?
ES6NHT1PJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHTGSnRKSzVyPUCuNFExQDNizszNNH\lTG1USU6JRWK=
NALM-6NVnLZpB7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MofVTWM2OD1yLkCxNVAzKM7:TR?=M3GwZnNCVkeHUh?=
LB996-RCCNVXBR4w2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIm5OZdKSzVyPUCuNFEyOzdizszNMnywV2FPT0WU
EW-16M3Xjd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnjKTWM2OD1yLkCxNVkzKM7:TR?=NHPVTnBUSU6JRWK=
KALS-1NWPvdHl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIj5eI9KSzVyPUCuNFEyQThizszNNHfvZZNUSU6JRWK=
OPM-2MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX;BUYdSUUN3ME2wMlAyOjlizszNMXvTRW5ITVJ?
KU812MlPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVH4VnZUUUN3ME2wMlAyOjl4IN88US=>NYDHc3JrW0GQR1XS
A4-FukNUXa[HNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2S4emlEPTB;MD6wNVMyQSEQvF2=NHHWbllUSU6JRWK=
KGNNXvlbVZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFvCWFNKSzVyPUCuNFE{PTlizszNMYrTRW5ITVJ?
KS-1MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnjpTWM2OD1yLkCxN|kzKM7:TR?=NWPGTZQzW0GQR1XS
no-11M4Pvfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGPBWJJKSzVyPUCuNFE{QTVizszNMX7TRW5ITVJ?
PSN1M{PBXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVnrdW1zUUN3ME2wMlAyPDB7IN88US=>NVfFOJFCW0GQR1XS
SK-LMS-1MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmSwTWM2OD1yLkCxOFE{KM7:TR?=M{T0WXNCVkeHUh?=
LS-411NNGT0N|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3vCbGlEPTB;MD6wNVQ{QSEQvF2=Mn7nV2FPT0WU
HT-144M2nBbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mnq4TWM2OD1yLkCxOFUyKM7:TR?=NU\4cIhDW0GQR1XS
ACNNWToXJVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NG\WPYtKSzVyPUCuNFE2KM7:TR?=MYrTRW5ITVJ?
RKOMULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIO5NYdKSzVyPUCuNFE2OzNizszNMnzaV2FPT0WU
CMKNXf5V2NLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2PVfWlEPTB;MD6wNVU1OyEQvF2=MV\TRW5ITVJ?
GB-1NV3RWGJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mmn5TWM2OD1yLkCxOVU{KM7:TR?=MYrTRW5ITVJ?
KE-37M3Ljd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXyzW3NtUUN3ME2wMlAyPTd|IN88US=>NXLhZVYyW0GQR1XS
no-10MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXLWXJBqUUN3ME2wMlAyPTh2IN88US=>MYrTRW5ITVJ?
MOLT-16MkXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{Hme2lEPTB;MD6wNVYzOiEQvF2=MUnTRW5ITVJ?
HELM3u2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH;ZOWVKSzVyPUCuNFE3PCEQvF2=NXLES5hxW0GQR1XS
NCI-H1355M3TmT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF7wVGFKSzVyPUCuNFE3PDZizszNMUTTRW5ITVJ?
IST-MEL1M{XkTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUfJR|UxRTBwMEG3O|Qh|ryPNH2wXmhUSU6JRWK=
MHH-PREB-1Ml\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFXVW4FKSzVyPUCuNFE5OThizszNNFz5cJpUSU6JRWK=
ES8NGToRVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGO5S49KSzVyPUCuNFE5PDRizszNMV\TRW5ITVJ?
LC-2-adM4K5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHnSU2pKSzVyPUCuNFIyOzdizszNNUHV[YloW0GQR1XS
LAMA-84NIXEfI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUHOXoIxUUN3ME2wMlAzOTZ5IN88US=>NYi1fXJ1W0GQR1XS
BV-173NE\B[3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUTJR|UxRTBwMEKyNFMh|ryPM4XOSnNCVkeHUh?=
SW872M3Pjc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYLJR|UxRTBwMEKyOFch|ryPMU\TRW5ITVJ?
SK-UT-1NXHZeJl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2\H[WlEPTB;MD6wNlI3OSEQvF2=MX\TRW5ITVJ?
OS-RC-2NF\FOXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYfJd3BGUUN3ME2wMlAzOzJ|IN88US=>NH3JcVhUSU6JRWK=
NCI-H747Ml\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX63dJB1UUN3ME2wMlAzOzNizszNM4fqS3NCVkeHUh?=
MZ2-MELM3f6Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEPKdJRKSzVyPUCuNFI{OzdizszNMXPTRW5ITVJ?
TE-11NETy[5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVvVO25XUUN3ME2wMlAzOzd{IN88US=>MlGxV2FPT0WU
KURAMOCHIMVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEO2VVVKSzVyPUCuNFI1OTRizszNMkK1V2FPT0WU
HD-MY-ZMX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXvsdGRXUUN3ME2wMlAzPDJ4IN88US=>NWPOeZFLW0GQR1XS
GI-1MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmrmTWM2OD1yLkCyOFY6KM7:TR?=NV7aVVFHW0GQR1XS
LB1047-RCCNH;OcHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1XQ[2lEPTB;MD6wNlQ5QCEQvF2=NVvqb3ZMW0GQR1XS
TE-12M2TJfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmfhTWM2OD1yLkCyOVUh|ryPNGjOOXFUSU6JRWK=
MZ7-melNF31VolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV2yb4M6UUN3ME2wMlAzPjB7IN88US=>NELxOoNUSU6JRWK=
MMAC-SFMYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mom4TWM2OD1yLkCyOlM{KM7:TR?=MWPTRW5ITVJ?
A101DNI[5NJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUHJR|UxRTBwMEK2OUDPxE1?NWqybHpLW0GQR1XS
GR-STMmDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnXZTWM2OD1yLkCyOlU2KM7:TR?=M3HvZnNCVkeHUh?=
MC116MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGrUOGZKSzVyPUCuNFI3QCEQvF2=MoryV2FPT0WU
Ramos-2G6-4C10M4[y[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX3JR|UxRTBwMEK3OUDPxE1?M3znPXNCVkeHUh?=
ATN-1MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXX0PYR{UUN3ME2wMlAzPzh7IN88US=>MkXIV2FPT0WU
MFH-inoNXnzV41GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkjOTWM2OD1yLkCyPFEzKM7:TR?=NVjMV2Y2W0GQR1XS
DELNFzFSYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mki0TWM2OD1yLkCyPFE2KM7:TR?=NGK1NohUSU6JRWK=
OCI-AML2MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn3ETWM2OD1yLkCyPFcyKM7:TR?=MoPnV2FPT0WU
LXF-289M2\UeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3jHbmlEPTB;MD6wNlg4OiEQvF2=NIrpSXRUSU6JRWK=
IA-LMMYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX7JR|UxRTBwMEK5NVch|ryPNID3cWZUSU6JRWK=
EoL-1-cellM4PL[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHXoWGJKSzVyPUCuNFI6QTZizszNNYLQe5NLW0GQR1XS
OVCAR-4MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUPJR|UxRTBwMEOwPVQh|ryPM2\MZnNCVkeHUh?=
ES1M2nKcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml7KTWM2OD1yLkCzNFk4KM7:TR?=NYTPc4l2W0GQR1XS
CESSNU\hVZduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn\FTWM2OD1yLkCzNFk6KM7:TR?=NETkWodUSU6JRWK=
GAKMmrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{DtfGlEPTB;MD6wN|E5PiEQvF2=M2LHPHNCVkeHUh?=
NTERA-S-cl-D1M3vWemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MU\JR|UxRTBwMEOyNlYh|ryPM{LQe3NCVkeHUh?=
TE-10M1XiT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHPEd2lKSzVyPUCuNFM{OTFizszNM{izSnNCVkeHUh?=
CCRF-CEMMly1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NInGfGJKSzVyPUCuNFM{PzFizszNM2DvdHNCVkeHUh?=
NMC-G1NEDlbpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV;JR|UxRTBwMEO0OFgh|ryPNUG5bngyW0GQR1XS
HOP-62NHm5SJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVr2XGY5UUN3ME2wMlA{PTV4IN88US=>Mo[0V2FPT0WU
SH-4NEnTNYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn;ETWM2OD1yLkCzOVgzKM7:TR?=M3;TeXNCVkeHUh?=
NCI-H1648NEPwS2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnHCTWM2OD1yLkCzOlIzKM7:TR?=MUPTRW5ITVJ?
EB-3MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVLJR|UxRTBwMEO2OFMh|ryPMnXiV2FPT0WU
BB65-RCCMnj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV;LW5dyUUN3ME2wMlA{PjlzIN88US=>M3L0dnNCVkeHUh?=
BE-13NWXIWo5tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUi1TVdbUUN3ME2wMlA{PzV7IN88US=>MVzTRW5ITVJ?
CP67-MELNIXrPXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3XkWWlEPTB;MD6wN|c2QSEQvF2=MVfTRW5ITVJ?
SW954MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFj3NHdKSzVyPUCuNFM4QSEQvF2=MkDFV2FPT0WU
TE-5MkXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{HhcWlEPTB;MD6wN|g2PCEQvF2=M3nufXNCVkeHUh?=
HCE-4MmDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NELMe2lKSzVyPUCuNFM5PTVizszNNXvPWHFlW0GQR1XS
LC-1FM{jWPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkjiTWM2OD1yLkCzPVg6KM7:TR?=MXjTRW5ITVJ?
TK10NWn0Z5VkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnHwTWM2OD1yLkC0NFE6KM7:TR?=MoW3V2FPT0WU
SJSA-1MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV31bmhWUUN3ME2wMlA1OTh6IN88US=>MnrkV2FPT0WU
DaudiNYL5S2RZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEPNdo9KSzVyPUCuNFQzOjVizszNM2nlZnNCVkeHUh?=
SW982M2\QT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWO3foRkUUN3ME2wMlA1OjR4IN88US=>MnfJV2FPT0WU
SF126Mk\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEOzeG5KSzVyPUCuNFQ{PjFizszNM1W0bnNCVkeHUh?=
TE-15M3u2UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3rU[mlEPTB;MD6wOFQ{PSEQvF2=NEnQdZRUSU6JRWK=
COLO-684NXHSR3JST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoLBTWM2OD1yLkC0OVYyKM7:TR?=NXLDfY1nW0GQR1XS
8-MG-BANF3ncHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGHpZ|BKSzVyPUCuNFQ3OjlizszNNYDQPYl6W0GQR1XS
NB13MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGnOOGFKSzVyPUCuNFQ4PzZizszNNH\QTVVUSU6JRWK=
HCC1599NXPFN5lHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX7NWYpbUUN3ME2wMlA1QDd7IN88US=>MlH6V2FPT0WU
SK-PN-DWM{fZU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXLqTGJ3UUN3ME2wMlA1QTR7IN88US=>NVnJbnNbW0GQR1XS
ALL-POM4nhSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYD1WGlWUUN3ME2wMlA1QTV4IN88US=>MUXTRW5ITVJ?
NB6MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIe3e5JKSzVyPUCuNFUzPzFizszNM33jO3NCVkeHUh?=
IST-SL2MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUmyWYVbUUN3ME2wMlA2OzZ{IN88US=>M2T0UXNCVkeHUh?=
BB30-HNCMV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3zRUWlEPTB;MD6wOVc{KM7:TR?=M{n0WHNCVkeHUh?=
SW962MoTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4e4c2lEPTB;MD6wOVc3OyEQvF2=Mnj1V2FPT0WU
TGBC24TKBMV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkHhTWM2OD1yLkC1O|k6KM7:TR?=NV74UWxDW0GQR1XS
KINGS-1MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWLibJFQUUN3ME2wMlA2QDB|IN88US=>MXnTRW5ITVJ?
HC-1NWL5O|BzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3vkWWlEPTB;MD6wOVgzPyEQvF2=NEP5N49USU6JRWK=
RS4-11MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4e3N2lEPTB;MD6wOVk{QCEQvF2=M2nxWHNCVkeHUh?=
LS-123Mm\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MY\JR|UxRTBwMEW5OFIh|ryPNEXKSINUSU6JRWK=
A3-KAWMmLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1jJXGlEPTB;MD6wOlIzPSEQvF2=MnGzV2FPT0WU
SNB75NETwRZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmX1TWM2OD1yLkC2N|QyKM7:TR?=M{HwWnNCVkeHUh?=
SRM3HZW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3fxc2lEPTB;MD6wOlM4PCEQvF2=NIrBUVZUSU6JRWK=
LOUCYMlXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mm\ETWM2OD1yLkC2N|k1KM7:TR?=NYS0fot3W0GQR1XS
K5NFradnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUHJR|UxRTBwME[0NFMh|ryPMXXTRW5ITVJ?
BeckerNIDyPHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NE\ZfHJKSzVyPUCuNFY1OiEQvF2=MYjTRW5ITVJ?
CTV-1MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXHJR|UxRTBwME[1OFgh|ryPM3PtV3NCVkeHUh?=
KLEMUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlX6TWM2OD1yLkC2OVg1KM7:TR?=MXzTRW5ITVJ?
MZ1-PCNEm0WIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYrJR|UxRTBwME[1PVgh|ryPM{Hl[nNCVkeHUh?=
MOLT-4MnLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFO0boRKSzVyPUCuNFY3ODVizszNMnf0V2FPT0WU
MLMAMmDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXrJR|UxRTBwME[3PEDPxE1?NIfrNVNUSU6JRWK=
A388MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkG1TWM2OD1yLkC2PFk{KM7:TR?=M2fXNXNCVkeHUh?=
MV-4-11MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2Pu[2lEPTB;MD6wOlk6PSEQvF2=NUWxSpZsW0GQR1XS
DSH1NH7IVFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mni5TWM2OD1yLkC3NVc{KM7:TR?=M1j5[HNCVkeHUh?=
MONO-MAC-6NWDGfVhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVnJR|UxRTBwMEeyNVIh|ryPNH;rSVRUSU6JRWK=
ARH-77MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml7LTWM2OD1yLkC3Nlc5KM7:TR?=NVPvcmU6W0GQR1XS
LB771-HNCMlLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYjJR|UxRTBwMEe1OFkh|ryPNXy3WIJMW0GQR1XS
PF-382NYjTWlFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnLNTWM2OD1yLkC3OVY6KM7:TR?=MnTRV2FPT0WU
KM12NFnZXIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYTacoFSUUN3ME2wMlA4PjRizszNNHfRZ2FUSU6JRWK=
HAL-01MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF;ZfFhKSzVyPUCuNFc3PThizszNM3nxbHNCVkeHUh?=
RPMI-8402NWXqcIRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWDJR|UxRTBwMEe3PFkh|ryPMVvTRW5ITVJ?
OMC-1MkTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmH4TWM2OD1yLkC3PFA1KM7:TR?=NX\6NVI1W0GQR1XS
HTMV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUHJR|UxRTBwMEig{txONEWwcYZUSU6JRWK=
QIMR-WILNYX3SnhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkDJTWM2OD1yLkC4NFU2KM7:TR?=NGmxbJJUSU6JRWK=
KNS-42NYKx[ZVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1\qTmlEPTB;MD6wPFIxOyEQvF2=NV7SSWw{W0GQR1XS
BC-3NX;0V41{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHzyUmpKSzVyPUCuNFgzODRizszNNFHNZWlUSU6JRWK=
ES4NVfVbo5xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmHBTWM2OD1yLkC4Nlk3KM7:TR?=NFzUeIdUSU6JRWK=
NCI-H23M4LnNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnLlTWM2OD1yLkC4OFQh|ryPM{jEUXNCVkeHUh?=
LB2518-MELMoLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3TtSWlEPTB;MD6wPFY6PiEQvF2=NGnoOmRUSU6JRWK=
LC4-1NFjVWWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVzJR|UxRTBwMEi3N|gh|ryPMUfTRW5ITVJ?
SIG-M5MnXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnTNTWM2OD1yLkC4PVA1KM7:TR?=M2\5fXNCVkeHUh?=
LP-1NX;OTlJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWTJR|UxRTBwMEi5N|gh|ryPMnXvV2FPT0WU
TE-8NVfTOJl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVPJR|UxRTBwMEmwNVYh|ryPNIK5SlhUSU6JRWK=
K-562MoHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWftNoVHUUN3ME2wMlA6OTJizszNNEjGd5dUSU6JRWK=
J-RT3-T3-5MmrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1vnN2lEPTB;MD6wPVE2OyEQvF2=MUPTRW5ITVJ?
DU-4475NInLPYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlPrTWM2OD1yLkC5NVY2KM7:TR?=MWfTRW5ITVJ?
RXF393NGjSS5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIj2PXVKSzVyPUCuNFk1PjJizszNNUW5[plrW0GQR1XS
NB5M1jaZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3rrNmlEPTB;MD6wPVYzPSEQvF2=MnP5V2FPT0WU
A704MmTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4nKU2lEPTB;MD6wPVc1OSEQvF2=MVPTRW5ITVJ?
SF268M4i4Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkTYTWM2OD1yLkC5PFI2KM7:TR?=NGPIZm5USU6JRWK=
UACC-257MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV3JR|UxRTBwMEm4N|Mh|ryPM3i2cXNCVkeHUh?=
L-428MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2DyZ2lEPTB;MD6xNFMzKM7:TR?=M2Pzd3NCVkeHUh?=
ST486MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWnJR|UxRTBwMUC2NFYh|ryPNGf4d2pUSU6JRWK=
SK-MM-2NX7DUJIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4[wTWlEPTB;MD6xNFcxQSEQvF2=NUXuUG1EW0GQR1XS
COR-L279M1\WV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFn2dodKSzVyPUCuNVA5OzJizszNM1O5OnNCVkeHUh?=
JiyoyeP-2003NIPTW|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIPCeoRKSzVyPUCuNVA5PDNizszNMkX1V2FPT0WU
GT3TKBNWSzdGpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXTJR|UxRTBwMUC5NVgh|ryPNHjxPG1USU6JRWK=
HCE-TMn\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFL6NGlKSzVyPUCuNVA6PCEQvF2=M{L1dnNCVkeHUh?=
SBC-1MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXzJR|UxRTBwMUGxNVkh|ryPNXz6bnYxW0GQR1XS
KNS-81-FDMlqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NG[0OHlKSzVyPUCuNVEzPzNizszNNUfxXZV[W0GQR1XS
NCI-H2126MlnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVzJR|UxRTBwMUGzPVQh|ryPMoHIV2FPT0WU
EM-2NXzuZ|Y4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHXVUo1KSzVyPUCuNVE2OjlizszNM2PGe3NCVkeHUh?=
JARMmOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUjXcmhwUUN3ME2wMlEyPTl6IN88US=>M{PDWXNCVkeHUh?=
NB17MoDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnrOTWM2OD1yLkGxOlUzKM7:TR?=NHfnfoxUSU6JRWK=
LB647-SCLCMmPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXjIfYM4UUN3ME2wMlEyPzB3IN88US=>NEjoco1USU6JRWK=
CAL-148NXKxPHBGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmnlTWM2OD1yLkGxPEDPxE1?MY\TRW5ITVJ?
K052Mnm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVnJR|UxRTBwMUG4OVEh|ryPNXm3c20{W0GQR1XS
KARPAS-299MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3;DRWlEPTB;MD6xNlI{OyEQvF2=NYnNWWJsW0GQR1XS
KARPAS-422NYrBeoxGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{HtXGlEPTB;MD6xNlQ{OiEQvF2=M{T2V3NCVkeHUh?=
LOXIMVIMl;aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmnzTWM2OD1yLkGyOVE2KM7:TR?=NXzucoZLW0GQR1XS
SCC-3MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHq2[WNKSzVyPUCuNVI5PTFizszNMlr6V2FPT0WU
LU-139M1XoNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWXJR|UxRTBwMUK5O|Uh|ryPMVTTRW5ITVJ?
COLO-320-HSRMlu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4PJcmlEPTB;MD6xN|A5PiEQvF2=MW\TRW5ITVJ?
ONS-76NHz3WYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVTq[HRHUUN3ME2wMlE{OTNizszNNEPocolUSU6JRWK=
U-266NVfqRmxJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWDyUFhHUUN3ME2wMlE{OjR3IN88US=>MoTFV2FPT0WU
HHNXvpOXdRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1HsRmlEPTB;MD6xN|U{PSEQvF2=MVrTRW5ITVJ?
BB49-HNCMV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHLOUJlKSzVyPUCuNVM2QDdizszNM{OxPHNCVkeHUh?=
NCI-SNU-5M3vsN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoLBTWM2OD1yLkGzOVk3KM7:TR?=NInr[m9USU6JRWK=
C2BBe1NYnnNpJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUjzZVRsUUN3ME2wMlE{PzR4IN88US=>NWK5VFY1W0GQR1XS
ML-2NEfUSFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn\HTWM2OD1yLkGzPVU{KM7:TR?=NYDrdo9jW0GQR1XS
SCHM2TnW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{HKcWlEPTB;MD6xN|k4PCEQvF2=M1PXT3NCVkeHUh?=
NCI-H82M2HRVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlvkTWM2OD1yLkG0NVA1KM7:TR?=M1XRfnNCVkeHUh?=
MDA-MB-134-VINULYVG9uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYDJR|UxRTBwMUSyOVIh|ryPMU\TRW5ITVJ?
SK-N-DZNF\DUmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUPLbo9kUUN3ME2wMlE1PzF7IN88US=>MmXmV2FPT0WU
HL-60M2j4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1jJWmlEPTB;MD6xOFkzKM7:TR?=MUfTRW5ITVJ?
LB373-MEL-DM{fTVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFjKXllKSzVyPUCuNVU2OzlizszNNUHxO4tKW0GQR1XS
LB831-BLCMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4i4V2lEPTB;MD6xOlA4PiEQvF2=M4XHfnNCVkeHUh?=
SK-NEP-1M2K2[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFTNcpNKSzVyPUCuNVYyODFizszNMWXTRW5ITVJ?
IMR-5NGWwW3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWDJR|UxRTBwMU[0PFMh|ryPM{TKe3NCVkeHUh?=
Calu-6M{TMSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXnJR|UxRTBwMU[1N|ch|ryPNIC3W|FUSU6JRWK=
NCI-H1882NE\OR4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV7JR|UxRTBwMU[3Nlgh|ryPNGjuVFZUSU6JRWK=
NCI-H446MlfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4XhSWlEPTB;MD6xOlg6OSEQvF2=NHXUN2pUSU6JRWK=
GI-ME-NNFzkO2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUXuUHMxUUN3ME2wMlE5ODJizszNMWHTRW5ITVJ?
MPP-89MkX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlPlTWM2OD1yLkG4NVIyKM7:TR?=NVXBbXVDW0GQR1XS
CGTH-W-1MkfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFjhZXNKSzVyPUCuNVg1OzZizszNMkPIV2FPT0WU
MEG-01NULU[WVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFPiWY5KSzVyPUCuNVg3OjhizszNMl;sV2FPT0WU
NCI-H748M4qxT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWHHbmF1UUN3ME2wMlE5QTFzIN88US=>MkjYV2FPT0WU
COLO-829NVnTVlVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIXNd2RKSzVyPUCuNlA3PzNizszNMYLTRW5ITVJ?
GOTONVf5cWNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3;XNmlEPTB;MD6yNFc{KM7:TR?=MVnTRW5ITVJ?
EW-3NXvCWYc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkfyTWM2OD1yLkKxO|E5KM7:TR?=MWrTRW5ITVJ?
KY821MkXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3rkTmlEPTB;MD6yNlA1PSEQvF2=NVjJd|djW0GQR1XS
CTB-1NV34cHlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFnMSXVKSzVyPUCuNlIzOjhizszNMlO5V2FPT0WU
TALL-1MkfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2j5Z2lEPTB;MD6yNlkzOSEQvF2=NWe3OopoW0GQR1XS
NCI-H209M2\vbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWrJR|UxRTBwMkK5OlIh|ryPMoW4V2FPT0WU
IST-MES1NHiybpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHK5NWhKSzVyPUCuNlM2OSEQvF2=NHLJO5JUSU6JRWK=
DMS-114NXPUb4RWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1K1e2lEPTB;MD6yN|k6OyEQvF2=MXnTRW5ITVJ?
SNU-C2BNWDndmRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV3RfpdKUUN3ME2wMlI1OzF4IN88US=>NHrBRnJUSU6JRWK=
DG-75NX;hSHpsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVizN|R3UUN3ME2wMlI3OTl3IN88US=>MoXsV2FPT0WU
D-336MGMluyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3XmbGlEPTB;MD6yOlU2PyEQvF2=M4rXUXNCVkeHUh?=
KMOE-2MlzTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2racmlEPTB;MD6yO|U{QCEQvF2=NHGwd3lUSU6JRWK=
NB1MmS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFvLTGNKSzVyPUCuNlc6OjZizszNMYXTRW5ITVJ?
RH-1NXnGUWgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVjzSYNqUUN3ME2wMlI4QTh7IN88US=>Moj5V2FPT0WU
TE-1NV3Ue4NQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVexSYF1UUN3ME2wMlI5PDd7IN88US=>NY[0W|c{W0GQR1XS
RPMI-6666NWnxU49kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVXJR|UxRTBwMki4OEDPxE1?M3jJeHNCVkeHUh?=
TE-9NXnmRZdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHzoflFKSzVyPUCuNlg6QDVizszNNYP5RplpW0GQR1XS
BT-474NFvubHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVHJR|UxRTBwMkmzN|Qh|ryPNXzjfJM{W0GQR1XS
COLO-668NYrnc|JXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{XObmlEPTB;MD6yPVQzQSEQvF2=MnvXV2FPT0WU
NCI-H1581MojRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M37rS2lEPTB;MD6yPVY5QSEQvF2=NHywdohUSU6JRWK=
MN-60M3jkVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFS3UHJKSzVyPUCuNlk6ODVizszNM1q5SnNCVkeHUh?=
L-540M1;ib2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mk\NTWM2OD1yLkOwNFgyKM7:TR?=NHL3e3BUSU6JRWK=
MOLT-13M4DRXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUfJR|UxRTBwM{CxPFMh|ryPNIHqZ4NUSU6JRWK=
NCI-SNU-16MnHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3Xxe2lEPTB;MD6zNFIxPSEQvF2=NXPCcZo1W0GQR1XS
NCI-H64MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXjkV2g5UUN3ME2wMlMxOzNzIN88US=>M1uzTnNCVkeHUh?=
CP66-MELNHjqOppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX3SVWc6UUN3ME2wMlMyPDF3IN88US=>MX\TRW5ITVJ?
NB69MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGLYWJZKSzVyPUCuN|IyQDhizszNMVLTRW5ITVJ?
NCI-H2196MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlXCTWM2OD1yLkOzNFM3KM7:TR?=MlfBV2FPT0WU
MHH-CALL-2MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXuwRmwxUUN3ME2wMlM{PDZ6IN88US=>NYTkUHJZW0GQR1XS
HCC2157MoHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4r4T2lEPTB;MD6zN|k2PCEQvF2=NYPmdIdyW0GQR1XS
LS-1034NIXNZopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEnUZoZKSzVyPUCuN|Y{QDhizszNMULTRW5ITVJ?
BOKUMYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2n3VWlEPTB;MD6zO|E6QSEQvF2=M1\MWHNCVkeHUh?=
GDM-1M{jlemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2\GZ2lEPTB;MD6zO|I{PCEQvF2=NYrFVXpOW0GQR1XS
TGWMlH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVjxSWdYUUN3ME2wMlM4PDV|IN88US=>MVTTRW5ITVJ?
SNU-C1M2X3RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX25fIlxUUN3ME2wMlM5OjF3IN88US=>M1\ZWXNCVkeHUh?=
LS-513M4PYUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUTJW5JiUUN3ME2wMlM6ODdzIN88US=>NFHmUY1USU6JRWK=
NOMO-1M3HQXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYnJR|UxRTBwM{m5O|Eh|ryPNXi1RZlmW0GQR1XS
MS-1NFHjWYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnG5TWM2OD1yLkSwNVc4KM7:TR?=MYTTRW5ITVJ?
EKVXNVnWfVdOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWrJR|UxRTBwNES0OlEh|ryPM135d3NCVkeHUh?=
SK-MEL-2M4DsSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUjrVGt4UUN3ME2wMlQ3PCEQvF2=NEnPcFdUSU6JRWK=
HCC1187NYL0cYFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3Wzc2lEPTB;MD60Olc3QCEQvF2=M320eXNCVkeHUh?=
HCC2218M3r2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVfFO3BDUUN3ME2wMlQ4OjJ5IN88US=>M2m1cHNCVkeHUh?=
NCI-H187MnjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYnJR|UxRTBwNEe4OEDPxE1?NVPVbXZuW0GQR1XS
DBMorLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVvP[JJ1UUN3ME2wMlUxODV3IN88US=>MXvTRW5ITVJ?
NCI-H69MoPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoS0TWM2OD1yLkWwNlQ4KM7:TR?=MVTTRW5ITVJ?
NCI-H1694M{XjOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn3LTWM2OD1yLkWwOlk4KM7:TR?=MXrTRW5ITVJ?
CA46NXnXdlc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGPxTW5KSzVyPUCuOVA6OTdizszNNIXQUJVUSU6JRWK=
EHEBMlu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFu2U2VKSzVyPUCuOVEyQTNizszNM2PrWnNCVkeHUh?=
NCCITNVG1TGJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWjJR|UxRTBwNUSzNlEh|ryPNUjXb|JsW0GQR1XS
NCI-H720MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHXQe4RKSzVyPUCuOVQ6PjJizszNMVTTRW5ITVJ?
LU-134-ANFizOmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4rRWmlEPTB;MD61OVI6PiEQvF2=M4XTd3NCVkeHUh?=
MC-CARNVjkSoVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVvJR|UxRTBwNUW0N|Eh|ryPNGrFRndUSU6JRWK=
NEC8NH\pR|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3\pUWlEPTB;MD61OlE4OiEQvF2=MmLjV2FPT0WU
NCI-H524NXnaOoR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3XYZ2lEPTB;MD61PFc1QCEQvF2=NHvCW2xUSU6JRWK=
NCI-H1963M4TQc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlLZTWM2OD1yLk[yOVgh|ryPNH7UelFUSU6JRWK=
SU-DHL-1NVftXFU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIfXSVlKSzVyPUCuOlQ2OjZizszNM2TNV3NCVkeHUh?=
NCI-H1522M1i2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkOxTWM2OD1yLk[0PFg{KM7:TR?=MVnTRW5ITVJ?
NCI-H1155MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXXJR|UxRTBwNkWzOUDPxE1?M{\NW3NCVkeHUh?=
D-263MGNUjST3c6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NES0bm9KSzVyPUCuOlYyODFizszNNFvnNlhUSU6JRWK=
TE-6Mnu2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mk\QTWM2OD1yLk[4NVA1KM7:TR?=Mn3IV2FPT0WU
NCI-H1417NFuyWXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmGwTWM2OD1yLk[5O|EyKM7:TR?=M3PE[3NCVkeHUh?=
NCI-H510ANFHQfnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmXHTWM2OD1yLke3NlM3KM7:TR?=MX;TRW5ITVJ?
KARPAS-45NWCyN4dUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{\OSWlEPTB;MD63PFI{PSEQvF2=M1:wTnNCVkeHUh?=
IST-SL1NVT2TJpxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1nXO2lEPTB;MD64OVgzPSEQvF2=MYLTRW5ITVJ?
COLO-824MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF3BUWVKSzVyPUCuPFc5OzVizszNNF;XNZJUSU6JRWK=
NCI-H526MoXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUnJR|UxRTBwOUC5OVgh|ryPMl\VV2FPT0WU
NCI-H719NXn3NZh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2j0N2lEPTB;MD65OlY2PyEQvF2=MlvJV2FPT0WU
SF539MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkLxTWM2OD1yLkm4N|k3KM7:TR?=NHrWXVBUSU6JRWK=
NKM-1M1[3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX;VeJZQUUN3ME2wMlk5PjZ|IN88US=>MYLTRW5ITVJ?
A253NV\KPGhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmjVTWM2OD1yLkm4PFg2KM7:TR?=MnTJV2FPT0WU
TE-441-TM3jo[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIC4TGxKSzVyPUGuNFQ{PSEQvF2=M4WxXnNCVkeHUh?=
COR-L88NFLTfFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX7s[VFsUUN3ME2xMlEyOzV2IN88US=>NXPCXmtTW0GQR1XS
CPC-NMXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFXGdG1KSzVyPUGuNVU5QDhizszNMWrTRW5ITVJ?
NCI-H2107Mn3NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NE\rVphKSzVyPUGuNVczPjFizszNMX\TRW5ITVJ?
ECC4MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYrmc3dxUUN3ME2xMlE5Pjl|IN88US=>NYPQNoU5W0GQR1XS
NCI-H2141M3r3cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYXoVYRDUUN3ME2xMlE6Ojl7IN88US=>MWDTRW5ITVJ?
NCI-H1770Mk\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEW3d5lKSzVyPUGuN|I6OjhizszNMl\yV2FPT0WU
NCI-SNU-1NXnGT492T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV6yNG85UUN3ME2xMlM{ODRizszNNUXTdHpJW0GQR1XS
LU-165Ml7HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUL2dZZCUUN3ME2xMlQ2PDZ5IN88US=>MXrTRW5ITVJ?
RajiNEX4fXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUDJR|UxRTFwNEeyOVkh|ryPNHL4TmdUSU6JRWK=
EW-24MoTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXTr[oZLUUN3ME2xMlU1PjF7IN88US=>MVPTRW5ITVJ?
KP-N-RT-BM-1MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWfJR|UxRTFwNU[1OVEh|ryPMkHKV2FPT0WU
SK-MEL-1NUTKcYwyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4PnTmlEPTB;MT62OFg4PyEQvF2=NHjVR3RUSU6JRWK=
SCLC-21HMUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEDt[3BKSzVyPUGuOlY3PTFizszNMlHtV2FPT0WU
SIMAM3:wdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV3HR|BsUUN3ME2xMlY5OjN|IN88US=>MXfTRW5ITVJ?
NCI-H1304MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVLJR|UxRTFwN{C3OlUh|ryPMmXIV2FPT0WU
REHNIL1NYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnPxTWM2OD1zLkexNFc5KM7:TR?=MmDoV2FPT0WU
KP-N-YSMkXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUOzXVdkUUN3ME2xMlk{PTVzIN88US=>MlvIV2FPT0WU
DMS-153MmDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1f6NWlEPTB;MT65O|U6KM7:TR?=MV7TRW5ITVJ?
NB10NWjXWGdWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVzOdnVHUUN3ME2yMlIxQDd6IN88US=>MmSxV2FPT0WU
NCI-H345NHn6dotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3H5UmlEPTB;Mj62NVkxPSEQvF2=MnLDV2FPT0WU
SK-N-FIMlK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3HuWWlEPTB;Mj63OVM5OSEQvF2=M1HadHNCVkeHUh?=
NCI-H1092NXq3UIx1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlTlTWM2OD1{Lkm1N|k1KM7:TR?=M3PZSXNCVkeHUh?=
KM-H2M1zTSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkfpTWM2OD1|Lk[1N|k3KM7:TR?=NYH4[XpuW0GQR1XS
KG-1NEXrZXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml\2TWM2OD1|LkexOlg5KM7:TR?=NXLtfJUyW0GQR1XS
D-283MEDM2jrVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlfUTWM2OD1|Lke1PFch|ryPMXXTRW5ITVJ?
LU-65NVHoWJhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXPJR|UxRTRwMUG0PFUh|ryPMnjiV2FPT0WU
MSTO-211HNETTNW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn21TWM2OD12LkG4PFk5KM7:TR?=NFvSPG9USU6JRWK=
NCI-H2081NEGz[XRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{XJPWlEPTB;ND6yPVE4PCEQvF2=NGrmPG5USU6JRWK=
D-247MGM1vweWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXXJR|UxRTRwNEOxPVEh|ryPNIj6TXNUSU6JRWK=
P31-FUJMmP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoWyTWM2OD12LkS1NFE6KM7:TR?=MmT1V2FPT0WU
DMS-79M2\1bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlXITWM2OD12LkmzNVg{KM7:TR?=M3Lvd3NCVkeHUh?=
KASUMI-1NWnKfXNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoX2TWM2OD12Lkm3OVA6KM7:TR?=Mn7nV2FPT0WU
JVM-3M{DhNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV3JR|UxRTVwMkWwNVQh|ryPNVG0NY11W0GQR1XS
LAN-6M3PIZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFXRb3dKSzVyPUWuOVE4OzZizszNNI\mUVdUSU6JRWK=
DJM-1M3XzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmPNTWM2OD13LkW2NFI6KM7:TR?=NVr5eXg5W0GQR1XS
JVM-2NGP5O|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYHJR|UxRTVwNkewPVIh|ryPMlz1V2FPT0WU
U-87-MGNULPfmg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmTDTWM2OD13Lki5PVY1KM7:TR?=NVPFWIM{W0GQR1XS
SHP-77NFvoeJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4\Dc2lEPTB;NT65OFkzQCEQvF2=MUXTRW5ITVJ?
RPMI-8866NXO2fIdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUfJR|UxRTZwMkewNVMh|ryPM1uwcHNCVkeHUh?=
ES7NXXhV5B4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MU\JR|UxRTZwM{m5NlQh|ryPNFTSb2FUSU6JRWK=
WSU-NHLNFjmV4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmftTWM2OD14LkWxOlA6KM7:TR?=MVXTRW5ITVJ?
CAS-1MkDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF\hRWNKSzVyPUeuNFk4PDlizszNMUDTRW5ITVJ?
MHH-NB-11MkDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUHJR|UxRThwMkOxOVIh|ryPNIrFSWdUSU6JRWK=
ES5Mk\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnfsTWM2OD17LkWyNlg3KM7:TR?=NWOwWHlRW0GQR1XS
HDLM-2NInMN5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MULJR|UxRTlwOUW5NFIh|ryPM4nHTHNCVkeHUh?=
NCI-H2171MoPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEWzelhKSzVyPUGwMlU6OjdizszNM{HpfXNCVkeHUh?=
LNCaP-Clone-FGCNXX2eFdwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXXJR|UxRTFzLkO3NVgh|ryPMU\TRW5ITVJ?
NCI-H1395MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3O0SGlEPTB;MUKuNlY6QSEQvF2=MWPTRW5ITVJ?
NCI-H1436MmHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXmxO5dlUUN3ME2xN{4{OTl3IN88US=>MnP2V2FPT0WU
RCC10RGBNWTSN2o4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlHRTWM2OD1zMz6zNlIyKM7:TR?=NWfwUmdUW0GQR1XS
SW684NGfme|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4DtO2lEPTB;MUOuPVc6PyEQvF2=NFTwc5VUSU6JRWK=
NCI-H1650M4rHVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlTyTWM2OD1zNT6wOFQ4KM7:TR?=MlfaV2FPT0WU
EW-13MkPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEHDW5BKSzVyPUG1MlIxOjFizszNM2HNenNCVkeHUh?=
EC-GI-10M4T1W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEjMTGxKSzVyPUG1Mlg3PDRizszNNWf1[2NSW0GQR1XS
CHP-126NHTTd|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlHWTWM2OD1zNz6xPVE5KM7:TR?=M3HyWnNCVkeHUh?=
NCI-H226MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUDJR|UxRTF6LkC0NFMh|ryPMUnTRW5ITVJ?
NCI-H1838M3m3OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIftNZRKSzVyPUKwMlE5PDhizszNM{HsRXNCVkeHUh?=
EW-11MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIDBVlhKSzVyPUK0MlI4OThizszNMmTWV2FPT0WU
EB2NVjrPFF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV7wUG1YUUN3ME2zNU42OzF6IN88US=>MlnNV2FPT0WU
D-502MGMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVzJR|UxRTR|LkmyNlkh|ryPM4LtO3NCVkeHUh?=
U-698-MMnfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYXJR|UxRTR6Lki2O|Eh|ryPMoLvV2FPT0WU
ES3MlKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGPNPWNKSzVyPUS5MlM5QTNizszNMYDTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Torin1 is efficacious at a dose of 20 mg/kg in a U87MG xenograft model and demonstrates good pharmacodynamic inhibition of downstream effectors of mTOR in tumor and peripheral tissues. [2]
Features

Protocol(Only for Reference)

Kinase Assay: [1]

mTORC1 and mTORC2 in Vitro Kinase Assays To produce soluble mTORC1, HEK-293T cell lines that stably express N-terminally FLAG-tagged Raptor are generated using vesicular stomatitis virus G-pseudotyped MSCV retrovirus. For mTORC2, similar HeLa cells that stably express N-terminally FLAG-tagged Protor-1 are generated. Both complexes are purified by lysing cells in 50 mm HEPES, pH 7.4, 10 mm sodium pyrophosphate, 10 mm sodium β-glycerophosphate, 100 mm NaCl, 2 mm EDTA, 0.3% CHAPS. Cells are lysed at 4 °C for 30 min, and the insoluble fraction is removed by microcentrifugation at 13,000 rpm for 10 min. Supernatants are incubated with FLAG-M2 monoclonal antibody-agarose for 1 h and then washed three times with lysis buffer and once with lysis buffer containing a final concentration of 0.5 M NaCl. Purified mTORC1 is eluted with 100 μg/mL 3×FLAG peptide in 50 mm HEPES, pH 7.4, 100 mm NaCl. Eluate can be aliquoted and stored at -80 °C. Substrates S6K1 and Akt1 are purified. Kinase assays are performed for 20 min at 30 °C in a final volume of 20 μL consisting of the kinase buffer (25 mm HEPES, pH 7.4, 50 mm KCl, 10 mm MgCl2, 500 μm ATP) and 150 ng of inactive S6K1 or Akt1 as substrates. Reactions are stopped by the addition of 80 μL of sample buffer and boiled for 5 min. Samples are subsequently analyzed by SDS-PAGE and immunoblotting.

Cell Assay: [1]

Cell lines MEFs
Concentrations ~250 nM
Incubation Time 4 days
Method Cell viability is assessed with the CellTiter-Glo Luminescent Cell Viability Assay. On Day 0, 96-well plates are seeded with 500 cells per well and grown overnight. On Day 1, cells are treated with the appropriate compounds and subsequently analyzed on Days 3-5. For analysis, plates are incubated for 60 min at room temperature; 50 μL of CellTiter-Glo reagent is added to each well, and plates are mixed on an orbital shaker for 12 min. Luminescence is quantified on a standard plate luminometer.

Animal Study: [2]

Animal Models U87MG xenograft model
Formulation Torin1 powder is first dissolved at 25 mg/mL in 100% N-methyl-2-pyrrolidone and subsequently diluted 1:4 with sterile 50% PEG400 to a final concentration of 5 mg/mL
Dosages 20 mg/kg
Administration Administered via i.p. once daily

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Thoreen CC, et al, J Biol Chem, 2009, 284(12), 8023-8032.

[2] Liu Q, et al, J Med Chem, 2010, 53(19), 7146-7155.

view more

Chemical Information

Download Torin 1 SDF
Molecular Weight (MW) 607.62
Formula

C35H28F3N5O2

CAS No. 1222998-36-8
Storage 3 years -20℃powder
2 years -80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 2 mg/mL (3.29 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 30% PEG 400+0.5% Tween80+5% Propylene glycol 30mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name Benzo[h]-1,6-naphthyridin-2(1H)-one, 1-[4-[4-(1-oxopropyl)-1-piperazinyl]-3-(trifluoromethyl)phenyl]-9-(3-quinolinyl)-

Frequently Asked Questions

  • Question 1
    How to re-constitute the inhibitor for i.p. administration?

    Answer: S2827 Torin 1 can be dissolved in 5% DMSO/30% PEG 300/ddH2O at 0.25 mg/ml clearly, and in 10% DMSO/corn oil at 0.5 mg/ml, it is also a clear solution.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related mTOR Products

  • MHY1485

    MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.

  • CHIR-99021 (CT99021)

    CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively.

  • Dorsomorphin

    Dorsomorphin is a potent, reversible, selective AMPK inhibitor with Ki of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.

  • Rapamycin (Sirolimus)

    Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

  • Everolimus (RAD001)

    Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay.

  • AZD8055

    AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. Phase 1.

    Features:First drug to inhibit both types of mTOR protein.

  • Temsirolimus (CCI-779, NSC 683864)

    Temsirolimus (CCI-779, NSC 683864) is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay.

  • INK 128 (MLN0128)

    INK 128 (MLN0128) is a potent and selective mTOR inhibitor with IC50 of 1 nM in cell-free assays; >200-fold less potent to class I PI3K isoforms, superior in blocking mTORC1/2 and sensitive to pro-invasion genes (vs Rapamycin). Phase 1.

  • Tacrolimus (FK506)

    Tacrolimus (FK506) is a 23-membered macrolide lactone, it reduces peptidyl-prolyl isomerase activity in T cells by binding to the immunophilin FKBP12 (FK506 binding protein) creating a new complex.

  • KU-0063794

    KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2 with IC50 of ~10 nM in cell-free assays; no effect on PI3Ks.

Recently Viewed Items

Tags: buy Torin 1 | Torin 1 supplier | purchase Torin 1 | Torin 1 cost | Torin 1 manufacturer | order Torin 1 | Torin 1 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us